Discover how Mark revitalizes his sunken raised garden bed in this in-depth update. Follow his organic gardening process as ...
Join Mark from Self Sufficient Me as he reveals his top five tips for successfully growing Rosella (also known as Roselle, ...
FDA authorization covers platinum-resistant disease after 1–3 prior lines, with mandatory prior bevacizumab exposure, ...
Corcept Therapeutics recently received U.S. FDA approval for Lifyorli (relacorilant) plus nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...
Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant ...
Onco360(R) , the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI(TM) (relacorilant), which is indicated in ...
Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant), which is indicated in ...
Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.
The drug can now be prescribed alongside nab-paclitaxel for patients with ovarian cancer who have relapsed between one and ...
FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results